Niels Møller

Medical Prognosis Institute A/S engages in the research and development of drugs and treatments for cancer and other related illnesses. It operates through the following segments: X Labs, Predict, Ventures, Personal, and Diagnostic business areas. The X Labs business area offers invent, prototype, and prove relevant techniques, scientific methodologies and business models. The Predict business area utilize the method to generate drug and patient response reports. The Ventures business area focuses on business development ventures. The Personal business area engages in developing business to consumer products and services. The Diagnostic business area operates lung chip diagnostics. The company was founded by Steen Knudsen in September 2004 and is headquartered in Horsholm, Denmark.

Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company is based in Boston, MA. Servier Pharmaceuticals continues to build a treatment portfolio with a current focus on oncology within acute lymphoblastic leukemia. The company invests in innovative research and development through development or partnerships to best address the unmet needs of patients. Additionally, the company is proud to offer financial assistance to not only support patients and their families but a variety of focused advocacy groups and healthcare professionals as well. Servier Pharmaceuticals is committed to engaging with patients, caregivers, families, and patient organizations to ensure their voices are heard in every initiative. The company's responsibility is to help make the world a better place for patients and their families, and it strives to have consistent and concise transparency throughout all clinical trials and research and development for the benefit of all patients. The company was founded in 1954. The CEO is David K. Lee.